Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment.
about
Gene therapy for lower urinary tract dysfunctionNeural control of the lower urinary tractNeural mechanisms underlying lower urinary tract dysfunctionAutonomic dysfunction and plasticity in micturition reflexes in human α-synuclein mice.Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder function.Changes in afferent activity after spinal cord injury.Bladder sensory physiology: neuroactive compounds and receptors, sensory transducers, and target-derived growth factors as targets to improve function.PACAP/VIP and receptor characterization in micturition pathways in mice with overexpression of NGF in urothelium.Neurotrophin/receptor expression in urinary bladder of mice with overexpression of NGF in urotheliumNGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndromeNear-infrared spectroscopy of the urinary bladder during voiding in men with lower urinary tract symptoms: a preliminary studyIncreased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapyBiomarkers in overactive bladder: a new objective and noninvasive tool?The association of urinary nerve growth factor levels with bladder outlet obstruction in womenAfferent nerve regulation of bladder function in health and disease.Urinary nerve growth factor in patients with detrusor overactivity.Lower Levels of Urinary Nerve Growth Factor Might Predict Recurrent Urinary Tract Infections in WomenRole of p75NTR in female rat urinary bladder with cyclophosphamide-induced cystitis.Repeated variate stress in male rats induces increased voiding frequency, somatic sensitivity, and urinary bladder nerve growth factor expression.Transcriptional and translational plasticity in rodent urinary bladder TRP channels with urinary bladder inflammation, bladder dysfunction, or postnatal maturation.Advances in intravesical therapy for urinary tract disorders.Increased TRPV4 expression in urinary bladder and lumbosacral dorsal root ganglia in mice with chronic overexpression of NGF in urothelium.Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.Novel biomarkers for overactive bladder.Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target.Non-invasive techniques in the diagnosis of bladder storage disorders.Neurotrophins as regulators of urinary bladder function.Biomarkers for lower urinary tract dysfunction.Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?Neurotrophins in bladder function: what do we know and where do we go from here?Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome.Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.Urinary nerve growth factor level in children with neurogenic bladder due to myelomeningocele.Diminished long-term recovery of peak flow rate (PFR) after robotic prostatectomy in men with baseline PFR <10 mL/s and incidental association with high-risk prostate cancer.PACAP/Receptor System in Urinary Bladder Dysfunction and Pelvic Pain Following Urinary Bladder Inflammation or Stress.New frontiers in molecular and imaging research on evaluation and diagnosis of bladder outlet obstruction in women.Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder.Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia.Effect of hyaluronic acid on urine nerve growth factor in cyclophosphamide-induced cystitis.Elevated CXC chemokines in urine noninvasively discriminate OAB from UTI.
P2860
Q26824783-2699FDD0-A1FC-4887-8CE5-BEAB64D4C566Q26828785-1E23CE12-7B55-4D74-AAB9-B3F28867B60EQ26852088-FB3B4C99-A223-4396-B8F1-055A774A3998Q33640037-8CBDC222-6C7E-4FD3-904D-AB7F8D5F15FDQ33728157-044B04A9-8542-4989-8201-CB32E08CE4FFQ33936100-FF8018F0-00D0-4C37-8045-D01F0F7D96CBQ34158044-770906CF-ACDF-4603-86E6-617A165419AAQ34204160-A27E3F00-D6D7-4C12-918A-2B55690ECECAQ34599842-71DECC1D-72AC-4E65-B06F-DBDDE668AC7AQ34774149-5DEF173E-6E7F-4800-9B33-6F12E10DB1B6Q34927633-58C0753A-917D-41BA-A69E-657982A7B46BQ35009629-8B88DA68-4F96-40FB-81E0-B1EAB04E0291Q35040019-86167238-CF77-43BF-BD88-BB7C1AA65257Q35671024-0595B3F0-4163-4F3D-838F-4133FF7FBA25Q36057867-409A26BE-684D-4CEB-8346-1393970C61A2Q36177484-F5D24E4F-7FCB-495D-99C0-61F2E9021ECCQ36760537-A7B4E83E-1F42-4958-B034-75893388AD48Q37018472-B2C698A2-7D8F-4DFA-90E1-95B1A9F4B701Q37054639-0DAB641D-127E-463F-A6B9-03D4B5B7BE61Q37058323-FF7614E0-63D2-4F49-87B1-EFFC8D534326Q37114371-5F97B16B-9224-4B94-BED3-1C25D08AD1AAQ37188799-4BC71E83-3C90-4C52-A7AC-E0187BCA9032Q37833959-5B847C96-FEA8-4578-9BD1-A73B6721E20EQ37842130-7A87B311-8ABF-4BBC-A6AF-F226C922D9C2Q37869049-2B39A626-29B3-4B96-8400-656192FBBB0FQ37903794-B43DA13A-3232-4C8F-87D3-583CFEF445D1Q38050405-08908BC4-EE6F-4282-AE6F-A077881529E6Q38056769-22760085-3B5B-4E29-9D81-F6FF9CF1ABC5Q38085020-7A246434-4052-4B50-80CB-8FB4EA4AB790Q38115263-EA90E78B-3578-4433-9119-D5100ABF4DB4Q38671606-73FA8EB6-B78A-463F-AA55-5A878D9E5D98Q39203746-0F2AF64F-E4D7-416B-B770-6F663D382C25Q39488918-F970D59E-1BE6-4C40-AC74-A2C5EFCE7E74Q46629812-A0949E31-B340-4368-BD92-6F93AFEA80A5Q47106917-0196A2CA-34E9-4BB0-AC9E-7DE52AB5B055Q47334117-C6D8D67A-5FB5-4522-90CA-C1E169E0F797Q47685480-FDBF8B57-E8BC-4ECC-96B3-A3979AB827C4Q48162550-57CBE7DC-A6A6-4979-A58C-308EEA3F67A0Q48261535-F49F35B8-5170-44DE-A87D-1D04F176CDF5Q50622540-C5D9633F-BFAE-49D8-A0F1-209CDF001F2A
P2860
Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Urinary nerve growth factor le ...... successful medical treatment.
@en
Urinary nerve growth factor le ...... successful medical treatment.
@nl
type
label
Urinary nerve growth factor le ...... successful medical treatment.
@en
Urinary nerve growth factor le ...... successful medical treatment.
@nl
prefLabel
Urinary nerve growth factor le ...... successful medical treatment.
@en
Urinary nerve growth factor le ...... successful medical treatment.
@nl
P1433
P1476
Urinary nerve growth factor le ...... successful medical treatment.
@en
P2093
Hann-Chorng Kuo
Hsin-Tzu Liu
P304
104-8; discussion 108
P356
10.1016/J.UROLOGY.2008.01.069
P407
P577
2008-04-08T00:00:00Z